CI-980 in advanced melanoma and hormone refractory prostate cancer

Christopher Ryan, Keith L. Shulman, Jon M. Richards, John W. Kugler, Jeffrey A. Sosman, Rafat H. Ansari, Everett E. Vokes, Nicholas J. Vogelzang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalInvestigational New Drugs
Volume18
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Melanoma
Prostatic Neoplasms
Neutropenia
Hormones
Drug Therapy
Tubulin
Tumor Cell Line
Polymerization
Immunotherapy
Prostate
Appointments and Schedules
Clinical Trials
canertinib dihydrochloride

Keywords

  • Chemotherapy
  • Clinical trial
  • Malignant melanoma
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Ryan, C., Shulman, K. L., Richards, J. M., Kugler, J. W., Sosman, J. A., Ansari, R. H., ... Vogelzang, N. J. (2000). CI-980 in advanced melanoma and hormone refractory prostate cancer. Investigational New Drugs, 18(2), 187-191. https://doi.org/10.1023/A:1006382014403

CI-980 in advanced melanoma and hormone refractory prostate cancer. / Ryan, Christopher; Shulman, Keith L.; Richards, Jon M.; Kugler, John W.; Sosman, Jeffrey A.; Ansari, Rafat H.; Vokes, Everett E.; Vogelzang, Nicholas J.

In: Investigational New Drugs, Vol. 18, No. 2, 2000, p. 187-191.

Research output: Contribution to journalArticle

Ryan, C, Shulman, KL, Richards, JM, Kugler, JW, Sosman, JA, Ansari, RH, Vokes, EE & Vogelzang, NJ 2000, 'CI-980 in advanced melanoma and hormone refractory prostate cancer', Investigational New Drugs, vol. 18, no. 2, pp. 187-191. https://doi.org/10.1023/A:1006382014403
Ryan, Christopher ; Shulman, Keith L. ; Richards, Jon M. ; Kugler, John W. ; Sosman, Jeffrey A. ; Ansari, Rafat H. ; Vokes, Everett E. ; Vogelzang, Nicholas J. / CI-980 in advanced melanoma and hormone refractory prostate cancer. In: Investigational New Drugs. 2000 ; Vol. 18, No. 2. pp. 187-191.
@article{1ac07bc8647a4dd590543541b6e8b865,
title = "CI-980 in advanced melanoma and hormone refractory prostate cancer",
abstract = "Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15{\%} and 31{\%} developed grade 3 and grade 4 neutropenia, while 7{\%} and 38{\%} of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.",
keywords = "Chemotherapy, Clinical trial, Malignant melanoma, Prostate cancer",
author = "Christopher Ryan and Shulman, {Keith L.} and Richards, {Jon M.} and Kugler, {John W.} and Sosman, {Jeffrey A.} and Ansari, {Rafat H.} and Vokes, {Everett E.} and Vogelzang, {Nicholas J.}",
year = "2000",
doi = "10.1023/A:1006382014403",
language = "English (US)",
volume = "18",
pages = "187--191",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - CI-980 in advanced melanoma and hormone refractory prostate cancer

AU - Ryan, Christopher

AU - Shulman, Keith L.

AU - Richards, Jon M.

AU - Kugler, John W.

AU - Sosman, Jeffrey A.

AU - Ansari, Rafat H.

AU - Vokes, Everett E.

AU - Vogelzang, Nicholas J.

PY - 2000

Y1 - 2000

N2 - Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

AB - Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

KW - Chemotherapy

KW - Clinical trial

KW - Malignant melanoma

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0034063541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034063541&partnerID=8YFLogxK

U2 - 10.1023/A:1006382014403

DO - 10.1023/A:1006382014403

M3 - Article

C2 - 10857996

AN - SCOPUS:0034063541

VL - 18

SP - 187

EP - 191

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -